JW Theriac

South Korea's JW Pharmaceutical Corp., announced on Monday that it has received approval from the Malaysian National Pharmaceutical Regulatory Age...

South Korea's JW Holdings corporation announced on Tuesday that it started to export the multi-nutritional liquid Winuf Central 736·1085ml to...

South Korea's JW Pharmaceutical Corp. on Thursday said it received approval from Thailand's Food and Drug Administration to conduct Phase 3 clinical...

South Korea's JW Pharmaceutical announced on Monday that its experimental hair loss drug, JW0061, has been selected for a two-year funding program b...

South Korea's JW Pharmaceutical has won approval from Taiwan's Food and Drug Administration (TFDA) to conduct phase 3 clinical trials for its gout t...

South Korea's JW Pharmaceutical on Wednesday released three products from its new incubator brand Hi-Mammi.The company's rollout of hybrid and high-...

South Korean drug developer JW Pharmaceutical has entered into a memorandum of understanding (MOU) with Zefit, a domestic non-clinical trial institu...

JW Pharmaceutical, a drug company based in South Korea, has received its first patent for a hair loss treatment that is currently in development. Th...

South Korea's drug developer JW Pharmaceutical is expanding the scope of its artificial intelligence (AI) uses from new drug research to the develop...

JW Pharmaceutical announced through its disclosure on Monday that it had applied last Friday for a phase 3 trial for Epaminurad, a gout treatment, w...

JW Pharmaceutical announced on Wednesday that it has relocated its US research center to Boston from San Diego. JW Theriac was first establishe...

JW Bioscience Co., a subsidiary of South Korea’s JW Life Science Co., has signed a non-exclusive agreement to transfer its patented technology...

JW Pharmaceutical Co. has become the first South Korean drug maker to develop the generic version of a next-generation antibiotic substance, the med...